Mylan Inc. on Tuesday confirmed it and several subsidiaries have been sued by Baxter International Inc., Baxter Healthcare Corp. and Baxter Healthcare SA in connection with the filing of an application with the U.S. Food and Drug Administration.
The application was for a generic version of Brevibloc, used to treat tachycardia, which is a fast or irregular heart rate.
Mylan (Nasdaq:MYL) said it believes that its subsidiary Agila is the first company to have filed a substantially complete abbreviated new drug application with the regulator and expects to be eligible for 180 days of marketing exclusivity upon receiving final FDA approval. Baxter filed lawsuits against the Mylan companies in the U.S. District Court for the District of New Jersey and the Northern District of West Virginia.
Mylan is based at Southpointe, near Pittsburgh.